Laboratory Corp. of America Holdings (NYSE:LH) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $140.66 and last traded at $140.52, with a volume of 424,234 shares traded. The stock had previously closed at $139.38.

A number of research analysts have issued reports on the company. SunTrust Banks Inc. reiterated a “buy” rating on shares of Laboratory Corp. of America Holdings in a research report on Thursday, July 28th. Canaccord Genuity set a $155.00 price target on Laboratory Corp. of America Holdings and gave the stock a “buy” rating in a research report on Thursday, July 28th. Evercore ISI boosted their price target on Laboratory Corp. of America Holdings from $147.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, July 27th. Credit Suisse Group AG reiterated an “outperform” rating and set a $143.00 price target (up previously from $135.00) on shares of Laboratory Corp. of America Holdings in a research report on Thursday, June 9th. Finally, KeyCorp reiterated a “buy” rating and set a $143.00 price target on shares of Laboratory Corp. of America Holdings in a research report on Sunday, May 22nd. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Laboratory Corp. of America Holdings presently has an average rating of “Buy” and a consensus target price of $138.15.

The company’s 50 day moving average is $133.64 and its 200 day moving average is $121.73. The company has a market capitalization of $14.34 billion and a price-to-earnings ratio of 23.27.

Laboratory Corp. of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, July 27th. The company reported $2.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.30 by $0.01. The company earned $2.40 billion during the quarter, compared to analyst estimates of $2.33 billion. During the same period in the previous year, the company posted $2.09 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. On average, analysts anticipate that Laboratory Corp. of America Holdings will post $8.82 EPS for the current year.

In related news, CEO David P. King sold 196,400 shares of the firm’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $128.00, for a total transaction of $25,139,200.00. Following the completion of the sale, the chief executive officer now directly owns 271,210 shares of the company’s stock, valued at approximately $34,714,880. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

A number of large investors have added to or reduced their stakes in LH. Victory Capital Management Inc. boosted its stake in Laboratory Corp. of America Holdings by 20.2% in the fourth quarter. Victory Capital Management Inc. now owns 9,223 shares of the company’s stock worth $1,140,000 after buying an additional 1,549 shares in the last quarter. Advantus Capital Management Inc boosted its stake in Laboratory Corp. of America Holdings by 3.5% in the fourth quarter. Advantus Capital Management Inc now owns 9,796 shares of the company’s stock worth $1,211,000 after buying an additional 332 shares in the last quarter. KBC Group NV boosted its stake in Laboratory Corp. of America Holdings by 14.9% in the fourth quarter. KBC Group NV now owns 11,077 shares of the company’s stock worth $1,370,000 after buying an additional 1,437 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in Laboratory Corp. of America Holdings by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 11,272 shares of the company’s stock worth $1,394,000 after buying an additional 61 shares in the last quarter. Finally, Suntrust Banks Inc. boosted its stake in Laboratory Corp. of America Holdings by 17.4% in the fourth quarter. Suntrust Banks Inc. now owns 13,227 shares of the company’s stock worth $1,633,000 after buying an additional 1,963 shares in the last quarter.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.